ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: The National Comprehensive Cancer Network guidelines list clinical trial as the top choice for all patients with PTCL (other than ALK+ ALCL) in both the first-line and relapsed/refractory settings.